1990-2023年美国州级慢性呼吸系统疾病负担及2050年预测:GBD 2023系统分析
基于GBD 2023数据,分析美国1990-2023年哮喘、慢阻肺、尘肺和间质性肺病/肺结节病的州级负担并预测至2050年。
核心结论
- 州级政策环境如烟草控制和疫苗接种可能影响呼吸健康结局。
- 整合控烟、公平疫苗接种和针对性卫生系统投资有助于应对不均衡负担。
研究设计与样本
- 基于GBD 2023数据的系统分析,估计美国四种慢性呼吸病负担。
- 按年龄、性别和年份分层,计算95%不确定性区间,并预测至2050年。
主要发现
- COPD和尘肺死亡率最高在阿巴拉契亚州,哮喘和ILD负担在南部和大平原地区升高。
关键数值与推荐
- 2023年哮喘、慢阻肺、ILD和肺结节病、尘肺的患病数分别为:未单独报告2023年分病种数据。
临床怎么用
- 关注州级政策差异,加强烟草控制和疫苗接种等预防措施。
- 针对高BMI、吸烟和职业暴露等可改变风险因素进行干预。
- 对高负担地区如阿巴拉契亚州和南部地区优化资源配置。
局限性
- 具体政策决定因素与结局的关联需进一步研究澄清。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic respiratory diseases are a leading cause of mortality in the USA, with considerable regional disparities influenced by environmental, occupational, and behavioural risk factors. This study aimed to quantify levels of, and trends in, the burden of chronic respiratory diseases in the USA from 1990 to 2023, with estimates of prevalence, mortality, and disability-adjusted life-years (DALYs); identify risk factors contributing to this burden; and project prevalence trends until 2050. METHODS: Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, we estimated the disease burden for four types of chronic respiratory disease: asthma, chronic obstructive pulmonary disease (COPD), pneumoconiosis, and interstitial lung disease (ILD) and pulmonary sarcoidosis. Estimates were stratified by age group, sex, and year from 1990 to 2023, along with corresponding 95% uncertainty intervals (UIs). Furthermore, we examined total percentage change before and during the COVID-19 pandemic, and forecast the future burden of chronic respiratory diseases through 2050. FINDINGS: In 2023, an estimated 54·50 million (95% UI 48·86-61·60) individuals lived with chronic respiratory disease in the USA, compared with 33·28 million (28·61-38·23) in 1990. The age-standardised prevalence rate increased by 10·24% (8·01-12·47) between 1990 and 2023, while the age-standardised mortality rate rose modestly from 31·19 (28·85-32·95) per 100 000 population to 34·56 (30·64-37·89) per 100 000 population, indicating persistent gaps in disease control. Marked geographical variation was observed, with the highest age-standardised mortality rates due to COPD and pneumoconiosis in Appalachian states (eg, Kentucky and West Virginia) and elevated asthma and ILD burden in the southern and Great Plains regions. Modifiable risk factors accounted for 44·54% (41·71-45·74) of total DALYs due to chronic respiratory diseases, driven mainly by high BMI for asthma, smoking for COPD, and occupational exposure to asthmagens for pneumoconiosis. Across the US states, higher cigarette taxation and broader respiratory infection vaccination coverage were linked to lower age-standardised DALY rates for COPD and ILD and pulmonary sarcoidosis, whereas asthma showed no consistent pattern. According to our projection models, by 2050, 45·72 million (28·96-67·27) individuals in the USA will have asthma, while 19·61 million (16·70-22·26) will have COPD, 1·05 million (0·74-1·44) will have ILD and pulmonary sarcoidosis, and 0·01 million (0·008-0·02) will have pneumoconiosis. INTERPRETATION: State-level policy environments, including fiscal and preventive health measures, might contribute to shaping respiratory health outcomes beyond individual risk factors. Integrating tobacco control measures, equitable vaccination programmes, and targeted health-system investments could help to address the uneven burden of chronic respiratory diseases across US states and the growing mortality gap despite stable prevalence, although further research is needed to clarify which specific policy determinants underlie these associations. FUNDING: Gates Foundation.
引用
- State-level burden of chronic respiratory diseases in the USA, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Respir Med. 2026. PMID: 42753772. doi:10.1016/S2213-2600(26)00218-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。